ATTY, DOCKET NO. APPLICATION NO. O9518,331	OLP E							D1-(6
FIRST SUBPLEMENT STATEMENT U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS DOCUMENT NAME ABI ABI ABI ACI ADI ACI ADI ACI ACI ACI AC		<u>.</u>			ATTY. DOCKET NO. 1488.1220002/EKS/PAJ FIRST NAMED INVENTOR APPLICATION NO. 09/518,381			
FIRST SUBPLEMENT STATEMENT U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS DOCUMENT NAME ABI ABI ABI ACI ADI ACI ADI ACI ACI ACI AC	LEB 1		FORM PTO-1449					
PACH NAME NAME CLASS SUB-CLASS FILING DATE	FIRST SURF	LEMEN		TION DISCLOSURI	FILING DATE			
PACH NAME NAME CLASS SUB-CLASS FILING DATE	A FRAUT.		STATEMENT	U.S. F		1164	46	······································
AA1	EXAMINER					CLASS	SUB-CLASS	EILING DATE
ACT AD1 AD1 AD1 AD1 AD1 AD1 AD1 AD		AA1	Nomber	5/112	TOME	ULAGG	300-02-03	TIENO DATE
AD1 AE1 2002/0052043 A1 05/02/2002 Li et al. AF1 AG1 AG1 AH1 AJ1 AK1 AK1 DOCUMENT FOREIGN PATENT DOCUMENTS INITIALE EXAMINER NUMBER DOCUMENT DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No Yes No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Birkenbach, M., et al., "Epstein-Barr Virus-Induced Genes: First Lymphocyte-Specific G Protein-Coupled Peptide Receptors," J. Virol. 67:2209-2220, American Society for Microbiology (1993) AT 4 EXAMINER Chattaraj, S.C., "Cangrelor AstraZoneca," Curr. Opin. Invest. Drugs 2:250-255, PharmaPress Ltd. DATE CONSPERSO DATE C		AB1			RFC	FIVE		
AE1 2002/0052043 A1 05/02/2002 Li et al. 04/09/2001 AF1 AG1 AG1 AH1 AJ1 AJ1 AK1 FOREIGN PATENT DOCUMENTS EXAMINER INITIAL AM1 AM1 AM1 AM1 AM1 AM1 AM1 AM1 AM1 AM		AC1				1 V E	-	
AG1 AG1 AH1 AJ1 AK1 EXAMINER INITIAL AND DOCUMENT DOCUMENTS EXAMINER INITIAL AL1 AK1 AK1 DOCUMENT DOCUMENTS FOREIGN PATENT DOCUMENTS COUNTRY CLASS SUB-CLASS TRANSLATION Yes No Yes No Yes No Yes No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR Birkenbach, M., et al., "Epstein-Barr Virus-Induced Genes: First Lymphocyte-Specific G Protein-Coupled Peptide Receptors," J. Virol. 67:2209-2220, American Society for Chattaraj, S.C., "Cangrelor AstraZeneca," Curr. Opin. Invest. Drugs 2:250-255, PharmaPress Ltd. EXAMINER DATE CONSIDERED		AD1			MAR	0 2 2004		
AG1 AH1 AJ1 AJ1 AK1 DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION YES NO OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR Birkenbach, M., et al., "Epstein-Barr Virus-Induced Genes: First Lymphocyte-Specific G Microbiology (1993) AT Chattaraj, S.C., "Cangrelor AstraZeneca," Curr. Opin. Invest. Drugs 2:250-255, PharmaPress Ltd. EXAMINER DATE CONSIDERED		AE1	2002/0052043	A1 05/02/2002	Li et al.			04/09/2001
AH1 AJ1 AJ1 AK1 DOCUMENT INITIAL EXAMINER INITIAL AM1 AM1 AM1 AM1 AM1 AM1 AM1 A		AF1						
AX1 AX1 AX1 AX1 AX1 AX1 AX1 DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No Yes No No No No No No No No No N		AG1						
EXAMINER DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No Yes No No No No No No No N		AH1						
EXAMINER AK1 DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No		Al1						
FOREIGN PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No		AJ1						
EXAMINER DOCUMENT DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No Yes Yes No Yes Ye		AK1			·			
AL1 AL1 AL1 AM1 WO 91/15583 A1 10/17/1991 WIPO AN1 WO 99/35106 A2 07/15/1999 WIPO AP1 OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR Birkenbach, M., et al., "Epstein-Barr Virus-Induced Genes: First Lymphocyte-Specific G Protein-Coupled Peptide Receptors," J. Virol. 67:2209-2220, American Society for Microbiology (1993) Chattaraj, S.C., "Cangrelor AstraZeneca," Curr. Opin. Invest. Drugs 2:250-255, PharmaPress Ltd. (February 2001) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Drugs in though citation is to conformance with MPEP 609, Drugs in though citation is to conformance with MPEP 609, Drugs in though citation is to conformance with MPEP 609, Drugs in though citation is to conformance with MPEP 609, Drugs in though citation is to conformance with MPEP 609, Drugs in though citation is to conformance with MPEP 609, Drugs in though citation is to conformance with MPEP 609, Drugs in though citation is to conformance with MPEP 609, Drugs in though citation is to conformance with MPEP 609, Drugs in though citation is to conformance with MPEP 609, Drugs in though citation is to conformance with MPEP 609, Drugs in though citation is to conformance with MPEP 609, Drugs in though citation is in conformance with MPEP 609, Drugs in though citation is in conformance with MPEP 609, Drugs in though citation is in conformance with MPEP 609, Drugs in though citation is in conformance with MPEP 609, Drugs in though citation is in conformance with MPEP 609, Drugs in though citation is in conformance with MPEP 609, Drugs in though citation is in conformance with MPEP 609, Drugs in though citation is in conformance with MPEP 609, Drugs in though citation is in conformance with MPEP 609, Drugs in the protein in t	EVAMINED		Localities	FOREIGN	PATENT DOCUMENTS			
AM1 AM1 AM1 WO 91/15583 A1 10/17/1991 WIPO AO1 WO 99/35106 A2 07/15/1999 WIPO AP1 OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR Birkenbach, M., et al., "Epstein-Barr Virus-Induced Genes: First Lymphocyte-Specific G Protein-Coupled Peptide Receptors," J. Virol. 67:2209-2220, American Society for Microbiology (1993) Chattaraj, S.C., "Cangrelor AstraZeneca," Curr. Opin. Invest. Drugs 2:250-255, PharmaPress Ltd. (February 2001) EXAMINER DATE CONSIDERED June DATE CONSIDERED June EXAMINER: Initial if reference considered, whether or not citation is in conformance with MEEP 600. Days less though district for line performance with MEEP 600. Days le				DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AM1 WO 91/15583 A1 10/17/1991 WIPO Yes No No Proceed to the Process of No No Process of No No Process of No No Process of No		AL1						Yes No
AN1 WO 91/15583 A1 10/17/1991 WIPO Yes No Ye		AM1						Yes
AC1 WO 99/35106 A2 07/15/1999 WIPO Yes No Yes No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR Birkenbach, M., et al., "Epstein-Barr Virus-Induced Genes: First Lymphocyte-Specific G Protein-Coupled Peptide Receptors," J. Virol. 67:2209-2220, American Society for Microbiology (1993) AT 4 Chattaraj, S.C., "Cangrelor AstraZeneca," Curr. Opin. Invest. Drugs 2:250-255, PharmaPress Ltd. (February 2001) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is one formance with MPEP 609. Draw line throug	NAP	AN1	WO 91/15583	A1 10/17/1991	WIPO			Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR Birkenbach, M., et al., "Epstein-Barr Virus-Induced Genes: First Lymphocyte-Specific G Protein-Coupled Peptide Receptors," J. Virol. 67:2209-2220, American Society for Microbiology (1993) AT Chattaraj, S.C., "Cangrelor AstraZeneca," Curr. Opin. Invest. Drugs 2:250-255, PharmaPress Ltd. (February 2001) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPER 609. Draw line through citation is no conformance with MPER 609.	NIV	AO1	WO 99/35106	A2 07/15/1999	WIPO			Yes No
AS 4 Birkenbach, M., et al., "Epstein-Barr Virus-Induced Genes: First Lymphocyte-Specific G Protein-Coupled Peptide Receptors," J. Virol. 67:2209-2220, American Society for Microbiology (1993) Chattaraj, S.C., "Cangrelor AstraZeneca," Curr. Opin. Invest. Drugs 2:250-255, PharmaPress Ltd. (February 2001) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPER 609. Draw line through citation if only perference considered, whether or not citation is in conformance with MPER 609. Draw line through citation if only perference considered.	•	AP1						Yes No
Birkenbach, M., et al., "Epstein-Barr Virus-Induced Genes: First Lymphocyte-Specific G Protein-Coupled Peptide Receptors," J. Virol. 67:2209-2220, American Society for Microbiology (1993) Chattaraj, S.C., "Cangrelor AstraZeneca," Curr. Opin. Invest. Drugs 2:250-255, PharmaPress Ltd. (February 2001) EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is in conformance with MPEP 609. Draw line through citation is no conformance with MPEP 609. Draw line through citation is no conformance with MPEP 609. Draw line through citation is no conformance with MPEP 609. Draw line through citation is no conformance with MPEP 609. Draw line through citation is no conformance with MPEP 609. Draw line through citation is no conformance with MPEP 609. Draw line through citation is no conformance with MPEP 609. Draw line through citation is no conformance with MPEP 609. Draw line through citation is no conformance with MPEP 609. Draw line through citation is no conformance with MPEP 609. Draw line through citation is no conformance with MPEP 609. Draw line through citation is no conformance with MPEP 609. Draw line through citation is no conformance with MPEP 609. Draw line through citation is no conformance with MPEP 609. Draw line through citation is no conformance with MPEP 609. Draw line through citation is no conformance with MPEP 609. Draw line through citation is no conformance.	-		OTHE	R (Including Aut	hor, Title, Date, Pertinent P	ages, etc.)		
Protein-Coupled Peptide Receptors," J. Virol. 67:2209-2220, American Society for Microbiology (1993) Chattaraj, S.C., "Cangrelor AstraZeneca," Curr. Opin. Invest. Drugs 2:250-255, PharmaPress Ltd. (February 2001) EXAMINER DATE CONSIDERED LEXAMINER: Initial if reference considered, whether or not citation is in conformance with MPER 609. Prayeling through citation is on conformance with MPER 609.		AR						
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPER 609. Draw line through citation if not in conformance with MPER 609. Draw line through citation if not in conformance with MPER 609. Draw line through citation if not in conformance with MPER 609. Draw line through citation if not in conformance with MPER 609. Draw line through citation if not in conformance with MPER 609.	Ny	AS	4 Protein-	Coupled Peptide	pstein-Barr Virus-Induced Ge Receptors," <i>J. Virol.</i> 67:2209	enes: First L -2220, Ame	ymphocyte-S rican Society	specific G v for
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPER 609. Draw line through citation if not in conformance with MPER 609. Draw line through citation if not in conformance with MPER 609.	ha	АТ		ij, S.C., "Cangrelor y 2001)	AstraZeneca," Curr. Opin. Invesi	t. Drugs 2:250	0-255, Pharma	Press Ltd.
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance	EXAMINER		Nine	<u> </u>		DATE C		10.
	EXAMINER: Initia	l if refere	nce considered, w	hether or not citation	is in conformance with MPEP 609. I	Draw line throu	gh citation if not	in conformance

OIP		Page 2 of 5
5	ATTY. DOCKET NO. 1488.1220002/EKS/PAJ	APPLICATION NO. 09/518,381
FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE	FIRST NAMED INVENTOR Li et al.	
* FIRST SUPPLEMENTAL INFORMATION DISCLOSURE	FILING DATE	ART UNIT
STATEMENT	March 3, 2000	1646
MACENARY		

MOEMAH				U.S.	PATENT DOCUMEN	TS					
EXAMINER INITIAL	AA	DOC	UMENT BER	DATE	NAME		CLASS	SUB-CLASS	FILING DATE		
		ļ				-					
	AB			,							
	AC										
	AD		· · · · · · ·			REC	EIVE				
	AE					LAAA	2 0 2 200	4			
	AF	1				(4)	Mar. (% ,	(
	AG										
<u> </u>	AH	<u> </u>						7			
	Al	-									
	AJ			<u> </u>		0.					
	AK										
EXAMINER		-		FOREIG	ON PATENT DOCUM	ENTS		1			
INITIAL			CUMENT MBER	DATE	COUNTRY		CLASS	SUB-CLASS	TRANSLATION		
	AL					-			Yes No		
	АМ								Yes		
	AN								No Yes		
	1	-					<u> </u>		No Yes		
	AO						<u> </u>		No Yes		
	AP		OTHER	(Including A	uthor, Title, Date, Per	tinent D	ages etc.)		No		
	AR	<u>5</u>	Connelly, I	K.P. and De W	itt, L.D., "Neurologic Conence Inc. (1994)			s Mononucleos	sis," Ped. Neurol.		
	AS	5	Grässer, F.A., et al., "Monoclonal Antibodies Directed Against the Epstein-Barr Virus-Encoded Nuclear Antigen 1 (EBNA1): Immunohistologic Detection of EBNA1 in the Malignant Cells of Hodgkin's Disease," Blood 84:3792-3798, The American Society for Hematology (1994)								
	AT	<u>5</u>	Hollopeter, Nature 409	Hollopeter, G., et al., "Identification of the platelet ADP receptor targeted by antithrombotic drugs," Nature 409:202-207, Nature Publishing Group (January 2001)							
EXAMINER		1	la				DATE	CONSIDERED	./.0		
EXAMINER: Initiand not consider	tial if refer	ende con	nsidered, whe	ther or not citati	on is in conformance with M	PEP 609.		alne	t in conformance		

229228_1.DOC

0186		Page 3 of 5
(C)	ATTY. DOCKET NO, 1488.1220002/EKS/PAJ	APPLICATION NO. 09/518,381
FORM PTO-1449	FIRST NAMED INVENTOR Li et al.	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE	FILING DATE	ART UNIT
STATEMENT	March 3, 2000	1646
TAADEMARK STATEMENT	_	

				U.S. PA	ATENT DOCUMENTS		-			
EXAMINER			UMENT							
INITIAL	AA	NUM	BER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE		
	AB					REC	EIVED			
	AC						0 2 2004	-		
	AD					WIPSIX	₩ <u>%</u> ~₩4			
	AE	<u> </u>								
	AF									
	AG									
	АН									
	Al									
	AJ	-								
	AK					 				
	<u> </u>	<u> </u>	1	FOREIGN	PATENT DOCUMENTS		L.,			
EXAMINER			CUMENT	6475	COLLITOR	[0115 01 100			
INITIAL	 	NUI	MBER	DATE	COUNTRY	CLASS	SUB-CLASS	Yes		
	AL					+		No Yes		
	AM							No Yes		
	AN							No Yes		
	AO	_						No		
	AP		OTHER (L		Title Date Date of			Yes No		
	1	1	OTHER (II	ncluding Auth	or, Title, Date, Pertinent F	ages, etc.)				
	AR	Kikuta, H., et al., "Detection of Epstein-Barr virus DNA in cardiac and aortic tissues from chronic, act Epstein-Barr virus infection associated with Kawasaki disease-like coronary artery aneurysms," J. P. 123:90-92, Mosby-Year Book, Inc. (1993)								
	AS	<u>6</u>	Schweickart Receptor En Inc. (1994)	Schweickart, V.L., et al., "Cloning of Human and Mouse EBI1, a Lymphoid-Specific G-Protein-Coupled Receptor Encoded on Human Chromosome 17q12-q21.2," <i>Genomics</i> 23:643-650, Academic Press, Inc. (1994)						
	AT	<u>6</u>		Tyson, A.A., Jr., et al., "Acute Epstein-Barr Virus Myocarditis Simulating Myocardial Infarction With Cardiogenic Shock," <i>South. Med. J. 82</i> :1184-1187, Southern Medical Association (1989)						
EXAMINER		<u>\</u>	w/ 1	R			ONSIDERED) h		
EXAMINER: Init	al if refer	ence co	nsidered, wheth	ner or not citation is	s in conformance with MPEP 609.	Draw line throu	igh citation if no	t in conformance		

OIPE		
/ 5\		Page 4 of 5
FEB 2 & 2004 14	ATTY. DOCKET NO. 1488.1220002/EKS/PAJ	APPLICATION NO. 09/518,381
FORM PTO-1449	FIRST NAMED INVENTOR Li et al.	
TO A STATE OF THE PROPERTY OF	FILING DATE	ART UNIT
STATEMENT	March 3, 2000	1646

				U.S	PATENT DOCUM	ENTS			
EXAMINER			UMENT						
NITIAL		NUM	IBER	DATE	NAME		CLASS	SUB-CLASS	FILING DATE
	AA	1							
	AB								
								<u> </u>	
	AC			 			_		1
	AD			- -		HE	CEIVE		
						-	CEIVE	٠	
	AE					MA	0 9 20	24	
	AF	╁──					U 20 EU(J4 .	
	AG								
	AH	 							
		l							
	Al								
	AJ			-			·		
-	AK								
	1	1		FORFI	GN PATENT DOC	JMENTS	· · ·		_1
EXAMINER		DO	CUMENT	- CINE	OILL ALLIN BOOK	<u> </u>	Ţ		
NITIAL	_	NU	MBER	DATE	COUNTRY		CLASS	SUB-CLASS	TRANSLATION
	AL								Yes No
	1/1						1		Yes
	AM								No
	AN	}						*	Yes No
	1	<u> </u>							Yes
	AO							-	No
	AP								Yes No
	17		OTHER	R (Including A	uthor, Title, Date,	Pertinent Pa	ages, etc.	1	140
	AR	7	Recanali	zation and Impr	de of the Platelet P2Y oves the Myocardial 3 sc. <i>Biol 22</i> :357-362, I	issue Perfusi	on in a Can	ine Thrombosis	Model,"
	AS	7	Databas	se EMBL, Acce	ession No. AA25442	25, Marra, M	., et al., (fi	st available M	larch 1997)
	AT	7	Partial E 17, 2003	European Sear 3, European P	ch Report for Europatent Office, Nether	ean Applica lands	tion No. 03		iled December
102.22.72.2		11			· ·				
XAMINER		X 1	18.0	(n			DATE	CONSIDERED	10

OIPE		
tr'		Page 5 of 5
/ mall	ATTY. DOCKET NO.	APPLICATION NO.
(3 8 2004 85)	1488.1220002/EKS/PAJ	09/518,381
FORM PTO-1449	FIRST NAMED INVENTOR	·
	Li et al.	
KAFIRST SURPLÉMENTAL INFORMATION DISCLOSURE	FILING DATE	ART UNIT
STATEMENT STATEMENT	March 3, 2000	1646

			• "	U.S. P.	ATENT DOCUMENTS			
EXAMINER			UMENT					
INITIAL	AA	NUM	BER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	~~							
	AB							
	AC	-				/ED	-	
					·			
	AD	İ			MAR 0 2	2004		
	AE	<u> </u>					_	
	AF				•			
	AG	 					<u> </u>	-
	AH							
	Al			······································				
	AJ							
ļ	AJ							
	AK					ı		
		<u> </u>		FOREICN	 PATENT DOCUMENTS			
EXAMINER	T	DO	CUMENT	FOREIGN			Т	-
INITIAL			MBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL							Yes
	AL						 	No Yes
	AM							No
	AN							Yes No
	'''				-			Yes
	AO							No.
	AP							Yes No
			OTHER (I	ncluding Autl	nor, Title, Date, Pertinent F	Pages, etc.))	
hr	AR	8	Copy of Co- 2000 (NOT	Pending Non-P PUBLISHED)	rovisional U.S. Patent Application	on No. 09/51	8,383, Li <i>et al.</i> , :	iiled March 3,
	AS							
	AT .							
EXAMINER		<u> </u> ~	1 n			DATE	CONSIDERED 6/W	(oh.
EXAMINER: Initia and not considere	at if refer	ence co	nsidered, whether	her or not citation	is in conformance with MPEP 609.	Draw line thro	ough citation if not	in conformance